incretin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
== Use in horticulture == Synthetic plant hormones or PGRs are used in a number of different techniques involving plant propagation from cuttings, grafting, micropropagation and tissue culture. Most commonly they are commercially available as "rooting hormone powder". The propagation of plants by cuttings of fully developed leaves, stems, or roots is performed by gardeners utilizing auxin as a rooting compound applied to the cut surface; the auxins are taken into the plant and promote root initiation. In grafting, auxin promotes callus tissue formation, which joins the surfaces of the graft together. In micropropagation, different PGRs are used to promote multiplication and then rooting of new plantlets. In the tissue-culturing of plant cells, PGRs are used to produce callus growth, multiplication, and rooting.
Hahn's intention was still to work in industry. He received an offer of employment from Eugen Fischer, the director of Kalle & Co. (and the father of organic chemist Hans Fischer), but a condition of employment was that Hahn had to have lived in another country and have a reasonable command of another language. With this in mind, and to improve his knowledge of English, Hahn took up a post at University College London in 1904, working under Sir William Ramsay, who was known for having discovered the noble gases. Here Hahn worked on radiochemistry, at that time a very new field. In early 1905, in the course of his work with salts of radium, Hahn discovered a new substance he called radiothorium (thorium-228), which at that time was believed to be a new radioactive element. In fact, it was an isotope of the known element thorium; the concept of an isotope, along with the term, was coined in 1913 by the British chemist Frederick Soddy. Ramsay was enthusiastic when yet another new element was found in his institute, and he intended to announce the discovery in a correspondingly suitable way. In accordance with tradition this was done before the committee of the venerable Royal Society. At the session of the Royal Society on 16 March 1905 Ramsay communicated Hahn's discovery of radiothorium. The Daily Telegraph informed its readers:
== Bibliography == Ackerman, A. Bernard; Almut Böer; Bruce Bennin; Geoffrey J. Gottlieb (2005). Histologic Diagnosis of Inflammatory Skin Diseases An Algorithmic Method Based on Pattern Analysis. Ardor Scribendi. ISBN 978-1-893357-25-9. Archived from the original on 21 April 2011. Moore, Keith L. et al. (2010) Clinically Oriented Anatomy 6th Ed
== Biochemistry == 2-Aminomuconic semialdehyde is an intermediate in the kynurenine pathway of tryptophan metabolism, which leads to picolinic acid or quinolinic acid. The enzyme aminocarboxymuconate-semialdehyde decarboxylase produces it from 2-amino-3-carboxymuconic semialdehyde, a compound which would form quinolinic acid in the absence of that enzyme.
Sources: en.wikipedia.org
=== Immunoaffinity === Another use for the procedure is the affinity purification of antibodies from blood serum. If the serum is known to contain antibodies against a specific antigen (for example if the serum comes from an organism immunized against the antigen concerned) then it can be used for the affinity purification of that antigen. This is also known as Immunoaffinity Chromatography. For example, if an organism is immunised against a GST-fusion protein it will produce antibodies against the fusion-protein, and possibly antibodies against the GST tag as well. The protein can then be covalently coupled to a solid support such as agarose and used as an affinity ligand in purifications of antibody from immune serum. For thoroughness, the GST protein and the GST-fusion protein can each be coupled separately. The serum is initially allowed to bind to the GST affinity matrix. This will remove antibodies against the GST part of the fusion protein. The serum is then separated from the solid support and allowed to bind to the GST-fusion protein matrix. This allows any antibodies that recognize the antigen to be captured on the solid support. Elution of the antibodies of interest is most often achieved using a low pH buffer such as glycine pH 2.8. The eluate is collected into a neutral tris or phosphate buffer, to neutralize the low pH elution buffer and halt any degradation of the antibody's activity.
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management. It can be administered by subcutaneous injection or taken orally. It is sold as a generic drug by several drug companies in the Indian and Canadian markets, and worldwide by its originator, Novo Nordisk, under the brand names Ozempic and Rybelsus for diabetes; under the brand name Wegovy for weight management; and under the brand names Wegovy and Kayshild for the treatment of metabolic-associated steatohepatitis (nonalcoholic steatohepatitis) and liver cirrhosis. Wegovy is also used to reduce the risk of heart attacks. Semaglutide is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain, and acts as a GLP-1 receptor agonist. The most common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. Semaglutide was approved for medical use in the United States in 2017, in Canada, the European Union and Japan in 2018, and in Australia in 2019. In 2023, it was the nineteenth most commonly prescribed medication in the United States, with more than 25 million prescriptions. It is on the World Health Organization's List of Essential Medicines.
=== Apodization in mass spectrometry === During oscillation within an Orbitrap, a transient signal may not be stable until the ions settle into their oscillations. Toward the end, subtle ion collisions add up to cause noticeable dephasing. This presents a problem for the Fourier transform, as it averages the oscillatory signal across the length of the time-domain measurement. Software allows "apodization", the removal of the front and back section of the transient signal from consideration in the FT calculation. Thus, apodization improves the resolution of the resulting mass spectrum. Another way to improve the quality of the transient is to wait to collect data until ions have settled into stable oscillatory motion within the trap.
Risperidone has been classified as a "qualitatively atypical" antipsychotic agent with a relatively low incidence of extrapyramidal side effects (when given at low doses) that has more pronounced serotonin antagonism than dopamine antagonism. Risperidone contains the functional groups of benzisoxazole and piperidine as part of its molecular structure. Although not a butyrophenone, it was developed with the structures of benperidol and ketanserin as a basis. It has actions at several 5-HT (serotonin) receptor subtypes. These are 5-HT2C, linked to weight gain, and 5-HT2A, linked to its antipsychotic action and relief of some of the extrapyramidal side effects experienced with typical antipsychotics. It has been found that D-amino acid oxidase, the enzyme that catalyses the breakdown of D-amino acids (e.g. D-alanine and D-serine — the neurotransmitters) is inhibited by risperidone. Risperidone acts on the following receptors: Dopamine receptors: This drug is an antagonist of the D1 (D1, and D5) as well as the D2 (D2, D3 and D4) family receptors, with 70-fold selectivity for the D2 family. It has "tight binding" properties, which means it has a long half-life. Like other antipsychotics, risperidone blocks the mesolimbic pathway, the prefrontal cortex limbic pathway, and the tuberoinfundibular pathway in the central nervous system. Risperidone may induce extrapyramidal side effects, akathisia and tremors, which is associated with diminished dopaminergic activity in the striatum.
Soldiers and ninja also used "pills", small ball-shaped medicinal rations consumed in emergencies or long missions, of which there were three types: hyorogan ("ration pills"), made with various flours, sugary substances, and spices to provide quick energy; kikatsugan ("hunger pills"), made with starchy ingredients to provide endurance; and suikitsugan ("thirst pills"), made from umeboshi, bakumondoto, and sugar to encourage saliva production. Tang dynasty soldiers ate primarily millet porridge, but before a deployment, they would have a large and elaborate banquet, with another large meal before a battle. Song dynasty soldiers were issued money for food and bought meat, vegetables, pickles, and salt locally. Grain supply issues meant they relied less on grain rations than in prior generations. During the Ming dynasty, sesame seed cakes, which could last long periods of time, became standard military food and wheat began to take an important position in rations. The imperial government spent significant amounts of money on the military, investing more into supplying the army with food than previous dynasties. A system of military farmlands, comprising 10% of cultivated land, was organized to supply the army. The state assigned 10% to 20% of military households in each region with running military farms and provided them with seeds and tools to grow grain. Other farmers delivered grain to supplement bad growing seasons. In 1392, this system was designed to feed 1.2 million soldiers.
Sources: en.wikipedia.org
Cold fission Fissile material Fission fragment reactor Hybrid fusion/fission Nuclear fusion Nuclear propulsion Photofission HD 101065 – Star in the constellation Centaurus which contain large amount of thorium, uranium and some short-lived radioactive isotopes.
Each new scientific advance became a media event designed to capture public support, and by the 1980s, biotechnology grew into a promising real industry. In 1988, only five proteins from genetically engineered cells had been approved as drugs by the United States Food and Drug Administration (FDA), but this number would skyrocket to over 125 by the end of the 1990s. The field of genetic engineering remains a heated topic of discussion in today's society with the advent of gene therapy, stem cell research, cloning, and genetically modified food. While it seems only natural nowadays to link pharmaceutical drugs as solutions to health and societal problems, this relationship of biotechnology serving social needs began centuries ago.
== Career == Harrington was a programmer at the video game developer Dynamix and a designer on the Windows NT operating system at Microsoft. In 1996, he founded Valve with Gabe Newell, another former Microsoft employee. Harrington sold his Microsoft shares to fund his half of the startup. His wife at the time, Monica Harrington, was Valve's marketing strategist in its early years. Harrington worked as a programmer on Valve's first game, Half-Life (1998), and funded its development with Newell. It was a critical and commercial success. Harrington said: "At Microsoft you always wonder, 'Is it me being successful or is it Microsoft?' But with Half-Life I knew Gabe and I had built that product and company from scratch." On January 15, 2000, Harrington sold his stake in Valve to Newell and left to spend time with his wife. According to Newell, Harrington did not want to risk another project after the success of Half-Life. In 2006, Harrington co-founded the photo editing service Picnik with his friend and former colleague Darrin Massena. Picnik was acquired by Google in March 2010. Harrington left Google in March 2011. In January 2012, he co-founded another company with Massena, Catnip Labs. Harrington was CTO at the Committee for Children from 2016 to 2018, and CTO of Amplion from November 2018 until March 2020.
Pitolisant is an inverse agonist (antagonist) of the histamine H3 autoreceptor. As such, pitolisant is an antihistamine medication that also belongs to the class of CNS stimulants. Pitolisant is also considered a medication of eugeroic class, which means that it promotes wakefulness and alertness. Pitolisant is the first wakefulness-promoting agent that acts by blocking the H3 autoreceptor. Pitolisant has been shown to be effective and well-tolerated for the treatment of narcolepsy with or without cataplexy. Pitolisant is the only non-controlled anti-narcoleptic drug in the United States. It has shown minimal abuse risk in studies. Blocking the histamine H3 autoreceptor increases the activity of histamine neurons in the brain. The H3 autoreceptors regulate histaminergic activity in the central nervous system (and to a lesser extent, the peripheral nervous system) by inhibiting histamine biosynthesis and release upon binding to endogenous histamine. By preventing the binding of endogenous histamine at the H3, as well as producing a response opposite to that of endogenous histamine at the receptor (inverse agonism), pitolisant enhances histaminergic activity in the brain.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.